Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL‐ACS)
- 5 February 2019
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 44 (3) , 471-478
Abstract
What is known and objective Myocardial infarction (MI) in young adults accounts for up to 10% of all cases. Regarding life expectancy and professional activity, it is extremely important to restore and maintain young patients’ full performance. Therefore, secondary prevention is especially vital in this group of patients. The paper focuses on the analysis of pharmacotherapy in young MI patients in Poland, assessing disparities between the European Society of Cardiology guidelines and clinical practice, and regional differences among the provinces. Methods The analysis was conducted using the data from a nationwide, observational, multicentre, prospective study—the Polish Registry of Acute Coronary Syndromes (PL‐ACS). The data were collected from patients ≤45 years old with MI who were hospitalized in the period 2010‐2014. Results and discussion A retrospective study included 6367 MI patients. They constituted 3.9% of all the patients with MI in Poland. Despite the fact that during hospitalization regional differences were observed in case of acetylsalicylic acid (range 70.3%‐93.8%), β‐blockers (range 50.0%‐79.6%), statins (range 53.4%‐85.7%) and angiotensin‐converting enzyme inhibitors (range 46.9%‐75.0%), the majority of patients received the drugs according to the guidelines. Regional differences found at discharge also regarded those medications, but the range of observed variations was smaller. On average, three‐quarter of patients received guideline‐recommended medications. Still, in some provinces, almost a quarter of patients were administered those medications only at discharge. What is new and conclusion In the study population, there were significant differences between the provinces regarding pharmacotherapy during hospitalization, which concerned major groups of medications. However, pharmacotherapy indicated at discharge revealed fewer regional differences and adhered to guideline recommendations to a greater extent. Nevertheless, there is still some room for improvement, especially with regard to pharmacotherapy during hospitalization.Keywords
This publication has 19 references indexed in Scilit:
- Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countriesEuropean Heart Journal: Acute Cardiovascular Care, 2013
- Effect of evidence‐based drug therapy on long‐term outcomes in patients discharged after myocardial infarction: a nested case–control study in ItalyPharmacoepidemiology and Drug Safety, 2013
- Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial InfarctionThe American Journal of Medicine, 2012
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2012
- Statins in acute coronary syndrome: very early initiation and benefitsTherapeutic Advances in Cardiovascular Disease, 2012
- Thirty-Year (1975 to 2005) Trends in the Incidence Rates, Clinical Features, Treatment Practices, and Short-Term Outcomes of Patients <55 Years of Age Hospitalized With an Initial Acute Myocardial InfarctionThe American Journal of Cardiology, 2011
- Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005BMJ, 2009
- Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After DischargeJACC, 2008
- The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practiceEuropean Heart Journal, 2004
- ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionThe Lancet, 1995